Ingevity (NGVT) reported Q4 adjusted earnings late Tuesday of $0.95 per diluted share, compared with a loss of $0.20 a year earlier.

Four analysts polled by FactSet expected non-GAAP EPS of $0.31.

Net sales in the three months ended Dec. 31 fell to $298.8 million from $371.7 million a year earlier.

Three analysts surveyed by FactSet expected $310.9 million.

The company expects 2025 sales of $1.3 billion to $1.4 billion.

Four analysts surveyed by FactSet project $1.45 billion.